Stocks · News reference
Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.56) by 21.43 percent. This is a 46.88 percent increase over losses of $(1.28) per share from
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Alzamend Neuro has been upgraded to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The upgrade reflects improving business fundamentals, with analysts raising consensus estimates by 59.6% over the past three months. The stock is positioned in the top 20% of Zacks-covered stocks and may experience near-term price appreciation.
Filed: 2026-09-29 AccNo: 0001214659-26-012132 Size: 1 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar